Our researchers are working on the production of a thermoresponsive gel formulation that can be used to deliver CAR-T cells to tumour and/or resection sites.

Instead of the CAR-T cells dispersing once they enter the bloodstream (which is useful when treating blood cancers but not when treating solid tumours), the gel keeps the CAR-T cells in the region where they are needed. The CAR-T cells disperse slowly over time, increasing their efficacy and killing capacity.